Mast Therapeutics Inc (NASDAQ:MSTX) has earned an average broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company. Mast Therapeutics’ rating score has declined by 67% from three months ago as a result of a number of analysts’ upgrades and downgrades.

Analysts have set a 1-year consensus target price of $3.00 for the company and are predicting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Mast Therapeutics an industry rank of 91 out of 265 based on the ratings given to its competitors.

A number of equities analysts have issued reports on the company. Roth Capital reiterated a “buy” rating and set a $2.00 price target on shares of Mast Therapeutics in a research note on Friday, July 15th. Maxim Group set a $5.00 price target on Mast Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 27th. Zacks Investment Research upgraded Mast Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 30th. Canaccord Genuity restated a “buy” rating and issued a $3.00 target price on shares of Mast Therapeutics in a research note on Thursday, July 28th. Finally, Laidlaw downgraded Mast Therapeutics to a “neutral” rating in a research note on Wednesday.

Mast Therapeutics (NASDAQ:MSTX) opened at 0.1331 on Tuesday. Mast Therapeutics has a 52 week low of $0.10 and a 52 week high of $0.71. The company’s market cap is $28.19 million. The stock’s 50 day moving average price is $0.45 and its 200-day moving average price is $0.38.

Mast Therapeutics (NASDAQ:MSTX) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, equities research analysts forecast that Mast Therapeutics will post ($0.21) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. increased its position in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent filing with the SEC. The fund owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned about 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent quarter.

5 Day Chart for NASDAQ:MSTX

Get a free copy of the Zacks research report on Mast Therapeutics (MSTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with's FREE daily email newsletter.